Φορτώνει......
Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With (212)Pb-TCMC-Trastuzumab
PURPOSE: One-year monitoring of patients receiving intraperitoneal (IP) (212)Pb-TCMC-trastuzumab to provide long-term safety and outcome data. A secondary objective was to study 7 tumor markers for correlation with outcome. METHODS: Eighteen patients with relapsed intra-abdominal human epidermal gro...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Am J Clin Oncol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Lippincott Williams & Wilkins
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5449266/ https://ncbi.nlm.nih.gov/pubmed/27906723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0000000000000353 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|